Life Science Investing Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Life Science Investing Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
Life Science Investing Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
Life Science Investing Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
Life Science Investing Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
